VivoSeq
Other

Neovascular

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Neovascular is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Unknown status5 · 50%
Completed4 · 40%
Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Not yet recruiting·KKim's Eye Hospital·Phase 4·NCT07187804·30 enrolled
Ranibizumab for the Inhibition of Neovascularization in Pterygia
Completed·UUniversity of Miami·Phase 1·NCT00768963·10 enrolled
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
Completed·OOsaka University·Phase 1·NCT00791570·17 enrolled
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
Completed·UUniversity of Miami·Phase 1·NCT00769145·5 enrolled
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Completed·RRush University Medical Center·Phase 1/2·NCT00606138·9 enrolled
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
Unknown status·KKim's Eye Hospital·Phase 4·NCT04655482·30 enrolled
Ranibizumab for Myopic Neovascularization
Unknown status·IInstituto de Olhos de Goiania·Phase 4·NCT01246089·20 enrolled
BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration
Unknown status·—·N/A·NCT04882956·40 enrolled
Strategies for Management of Corneal Neovascularisation
Unknown status·UUniversity of Nottingham·Phase 4·NCT02594423·40 enrolled
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Unknown status·—·Phase 4·NCT04690062·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)